Capreomycin
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Capreomycin: Cyclic peptide antibiotic (ribosome-targeting) → Gout
One-Sentence Summary
Capreomycin is an injectable cyclic peptide antibiotic used against mycobacterial infection. The TxGNN model predicts it may be effective for gout, but no clinical trials and no publications were found in the data compiled for this report, so this is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | gout |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (7 of 7) – CDSCO approval status is not included in this data |
| Number of Listed Products | 7 (valid: 7) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Capreomycin belongs to the cyclic peptide, aminoglycoside-like antibiotic class, which is understood to act by binding the bacterial ribosome and inhibiting protein synthesis.
Gout is driven by inflammation triggered by urate crystals in the joints. No established link connects ribosomal inhibition to urate metabolism or crystal-induced inflammation, so no clear mechanistic link was identified. The high score of 0.9991 is a model output only. It is not supported by any trial or publication.
Capreomycin’s known kidney toxicity and electrolyte disturbances would also be unfavourable in gout patients, who often have kidney problems.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 51890 | Capreo 500mg Injection | vial of 1 Injection | Not recorded |
| 117896 | Kapocin 500mg Injection | vial of 1 Injection | Not recorded |
| 50929 | Ciprix 500mg Injection | vial of 1 Injection | Not recorded |
| 51078 | Ciprix 1000mg Injection | vial of 1 Injection | Not recorded |
| 117665 | Kapocin 1gm Injection | vial of 1 Injection | Not recorded |
Safety Considerations
- Drug Interactions: 58 interactions were identified. Two are rated Major: kanamycin and neomycin. Both are aminoglycosides, so additive kidney and hearing toxicity is a concern. Many others are rated Moderate, including amphotericin B (several formulations), corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, beclomethasone), proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, rabeprazole, dexlansoprazole), mesalazine-type drugs (mesalazine, balsalazide, olsalazine) and exenatide.
For label warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no trials or publications, no plausible mechanism linking capreomycin to gout, and the toxicity profile and injection-only route make long-term use in gout impractical.
To proceed, the following is needed:
- Mechanism-of-action data and any biological rationale linking capreomycin to urate handling or crystal-induced inflammation
- Preclinical or in vitro evidence in a gout model
- Package insert warnings and contraindications, to assess kidney, hearing and electrolyte risks
- A comparison against existing gout therapies, which are oral and well established
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.